The present study represents the first large‐scale, real‐world, comparative analysis of PD‐1 and PD‐L1 inhibitors in advanced NSCLC, revealing novel survival hierarchies and clinically actionable distinctions. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.